PODD NASDAQ
Insulet Corp.
1W: +5.1%
1M: +9.7%
3M: -10.9%
YTD: -47.2%
1Y: -53.9%
3Y: +2.8%
5Y: -48.9%
$149.83
+0.57 (+0.38%)
After Hours: $149.12 (-0.71, -0.47%)
Weekly Expected Move ±4.4%
$136
$143
$149
$156
$162
Credit Risk of going bust: lower than 65% of companies Debt: 8.4% of company value Bonds: $39.1M held by 117 funds, 168 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.35 (down 99.1%), Insulet Corp. would be worth roughly what it owes.
Total debt $948.4M against a stock market value of $10.35B.
Distance to default 6.86 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $483.6M (short-term plus half of long-term), stock volatility 46.5%; Altman Z 5.74. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.35 (down 99.1%), Insulet Corp. would be worth roughly what it owes.
Total debt $948.4M against a stock market value of $10.35B.
Distance to default 6.86 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $483.6M (short-term plus half of long-term), stock volatility 46.5%; Altman Z 5.74. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
From worst to first? These battered S&P 500 stocks bounce back
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Insulet Corporation $PODD Stock: Counterpoint Mutual Funds LLC Lowers Holdings
Insulet Corporation $PODD Shares Sold by Curated Wealth Partners LLC
Here's Why Insulet (PODD) is a Strong Growth Stock
Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTech
Moderna, Illumina lead healthcare gains in September as medtech drags
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
$1.2M yolo into $TNDM (Tandem Diabetes)
Andra AP fonden Sells 5,980 Shares of Insulet Corporation $PODD
S&P 500 nears record level, but breadth shows signs of stress
Nykredit A S Makes New Investment in Insulet Corporation $PODD
10 mid-cap U.S. healthcare stocks with the weakest momentum grades
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
California State Teachers Retirement System Has $2.22 Billion Stock Position in Insulet Corporation $PODD
Insulet Corporation $PODD Stock Position Raised by Amundi
Here's Why Insulet (PODD) is a Strong Growth Stock
Hsbc Holdings PLC Lowers Stake in Insulet Corporation $PODD
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
Insulet (PODD) is a Top-Ranked Value Stock: Should You Buy?
Empowered Funds LLC Acquires New Holdings in Insulet Corporation $PODD
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Ten healthcare stocks leading in year-over-year CapEx growth
American Capital Management Inc. Takes $4.49 Million Position in Insulet Corporation $PODD
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
Algert Global LLC Acquires 62,277 Shares of Insulet Corporation $PODD
Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?
BlackRock Inc. Takes Position in Insulet Corporation $PODD
14,672 Shares in Insulet Corporation $PODD Purchased by Aurora Investment Counsel
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Insulet (PODD) Q2 2026 Earnings Call Transcript
Here's Why Insulet (PODD) is a Strong Value Stock
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say
Insulet (PODD) Beats Q2 Earnings and Revenue Estimates
Important Notice to Long-Term Shareholders of EquipmentShare.com, Inc. (NASDAQ: EQPT); Insulet Corporation (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (f/k/a New Era Helium (NASDAQ: NEHC)); and Planet Fitness, Inc. (NYSE: PLNT): Grabar Law Office is Investigating Claims on Your Behalf
GE HealthCare Technologies (GEHC) Beats Q2 Earnings and Revenue Estimates
Bank of New York Mellon Corp Sells 15,303 Shares of Insulet Corporation $PODD
Three themes emerge as AI momentum trade turns volatile: Goldman Sachs
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Stock futures slide as chip stocks extend global rout
Ithaka Group adds TSM, LRCX; exits NFLX, INTU among Q2 moves
Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago
Here's Why Insulet (PODD) is a Strong Growth Stock
Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
Why Insulet (PODD) Could Beat Earnings Estimates Again
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Insulet Omnipod recall listed as Class I by FDA
Do Options Traders Know Something About Insulet Stock We Don't?
Here's Why Insulet (PODD) is a Strong Momentum Stock
Insulet (PODD) Just Overtook the 50-Day Moving Average
If You Invested $1000 in Insulet 10 Years Ago, This Is How Much You'd Have Now
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Insulet Corporation Stock: Is PODD Underperforming the Healthcare Sector?
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation
Is Insulet Corporation (PODD) A Good Stock To Buy Now?
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Bought $PLNT, $AVGO, $PODD. Thoughts?
Notable healthcare headlines for the week: UnitedHealth, Medtronic, and Eli Lilly in focus
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
TNDM Stock: What to Know About Tandem's 2026 Reset
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?
Insulet Corporation (PODD) Initiates Voluntary Correction For Certain Omnipod Devices
Notable healthcare headlines for the week: UnitedHealthcare, Pfizer, Eli Lilly in focus
Tandem Diabetes ($TNDM) 10x play or getting bought out privately in the next few years ($825k bet)
PODD Stock: What a Hold Rating Says at a $163 Target
Dow Jones Hit Records Above 50,600 As Oil Sinks Below $90: Stock Market Today
PODD and Omnipod 5: What's Driving Insulet's 2026 Growth
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Why Goldman Sachs Trimmed Insulet Corporation (PODD) Price Target Despite Strong Q1 Results
Here's Why Insulet (PODD) is a Strong Growth Stock
Why Insulet (PODD) is a Top Value Stock for the Long-Term
Notable healthcare headlines for the week: UnitedHealth, Pfizer, and CVS Health in focus
Most healthcare companies report higher Y/Y EPS in strong earnings week
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook
Earnings Scheduled For May 6, 2026
S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today
Insulet Corporation Q1 2026 Earnings Call Summary
Insulet forecasts 21%-23% 2026 revenue growth as it raises full-year outlook and targets ~100 bps margin expansion
Insulet (PODD) Q1 2026 Earnings Transcript
Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Transcript: Insulet Q1 2026 Earnings Conference Call
Insulet (PODD) Q1 Earnings and Revenues Top Estimates
Insulet Boosts 2026 Outlook Fueled By Strong Omnipod Growth
Insulet Q1 2026 Earnings Preview
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
Insulet (PODD) Upgraded to Buy: Here's Why
S&P 500 surges over 10% in April; Detrick says history favors more gains
Rothschild & Co Redburn Downgrades Insulet Corporation (PODD), Cites “Eroding” Product Moats and Distribution
PAHC vs. PODD: Which Stock Is the Better Value Option?
FDA Flags High-Risk Recall Of Insulet's Omnipod 5 Pods Over Insulin Delivery Concerns
Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth
Jim Cramer on Insulet Corporation: “It’s Still Too Expensive Because of the GLP-1 Threat”